Siga Technologies Inc. (NASDAQ:SIGA – Get Free Report) saw unusually large options trading activity on Wednesday. Investors bought 1,200 call options on the stock. This represents an increase of approximately 1,438% compared to the average volume of 78 call options.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Siga Technologies from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings lowered Siga Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Siga Technologies currently has an average rating of “Sell”.
Get Our Latest Report on Siga Technologies
Institutional Trading of Siga Technologies
Siga Technologies Price Performance
Siga Technologies stock opened at $6.73 on Thursday. Siga Technologies has a fifty-two week low of $4.95 and a fifty-two week high of $9.62. The firm has a fifty day moving average price of $6.44 and a two-hundred day moving average price of $7.46. The firm has a market cap of $481.94 million, a price-to-earnings ratio of 6.60 and a beta of 0.96.
Siga Technologies (NASDAQ:SIGA – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $2.62 million during the quarter. Siga Technologies had a net margin of 43.22% and a return on equity of 35.23%. As a group, sell-side analysts expect that Siga Technologies will post 1.04 earnings per share for the current year.
About Siga Technologies
Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.
Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.
Featured Stories
- Five stocks we like better than Siga Technologies
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Forget AI, This Will Be the Next Big Tech Breakthrough
- New gold price target
- Trump Planning to Use Public Law 63-43: Prepare Now
Receive News & Ratings for Siga Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siga Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
